Fundraising Fox

Timothy Perera

Founder

Founder & CEO at Deuteroncology

Liège, Walloon Region, Belgium

FoundedDeuteroncology

Find your path to Timothy

3,357 people in our graph share verified history with Timothy — schools, employers, funds. One of them is your warm intro.

About

Timothy Perera is the Founder and CEO of DeuterOncology NV, a biotech company he established in 2020 to develop DO-2, a deuterated MET kinase inhibitor for cancer treatment. He holds a Ph.D. in Cell Biology and has over 30 years of experience in oncology, along with patents, publications, and awards in the field. He previously co-founded OCTIMET Oncology NV, a spin-off of Janssen Pharmaceuticals, where he served as Chief Scientific Officer and led development of the MET/OCT-2 inhibitor OMO-1 through phase 1/2 clinical trials and raised over 12 million euros in funding.

Founder & CEO at Deuteroncology

Intro paths

→

In turn, Timothy can intro founders to Deuteroncology's investors below.

Deuteroncology's investors · 1

Newton BiocapitalBrussels

Experience

  1. DeuterOncology NVFounder and CEOcurrent2020 — presentWaloon Region, Belgium
  2. OCTIMET Oncology NVChief Scientific Officercurrent2016 — presentAntwerp Metropolitan Area
  3. OCTIMET Oncology LtdFounder2015 — 2016Greater Oxford Area
  4. Janssen, Pharmaceutical Companies of Johnson and JohnsonScientific Director and Janssen Fellow2013 — 2015Beerse, Belgium
  5. Janssen, Pharmaceutical Companies of Johnson and JohnsonGlobal Discovery Leader Lung Disease Area2011 — 2013Beerse, Belgium
  6. Johnson & JohnsonSection Head Cancer Biology2010 — 2011Beerse, Belgium
  7. Johnson & JohnsonResearch Fellow2007 — 2010Beerse Belgium
  8. Janssen-OrthoPrincipal Scientist2002 — 2007Beerse Belgium
  9. Yamnouchi Research Institute (UK) LtdTeam Leader Metabolic Disease Group1997 — 2002Greater Oxford Area
  10. Yamanouchi Research Institute (UK) LtdSenior Scientist II1994 — 1997Greater Oxford Area
  11. Yamanouchi Research Institute (UK LtdSenior Scientist 11991 — 1994Greater Oxford Area
  12. Royal Postgraduate Medical SchoolSenior Research Officer1988 — 1990London Area, United Kingdom

Skills & more

Cell4Immunology4Biomarkers4Validation4Biotechnology13Oncology9Pharmaceutical Industry12Drug Development10Clinical Development4Drug Discovery29Genomics2Lifesciences6
+9 moreTechnology TransferVaccinesR&DPharmacologyAssay DevelopmentMolecular BiologyProtein ChemistryInfectious DiseasesClinical Trials

Languages Dutch · English · French · Sinhalese

From Timothy's professional profile.

Frequently asked questions

Who is Timothy Perera?
Timothy Perera is the Founder and CEO of DeuterOncology NV, a biotech company he established in 2020 to develop DO-2, a deuterated MET kinase inhibitor for cancer treatment. He holds a Ph.D. in Cell Biology and has over 30 years of experience in oncology, along with patents, publications, and awards in the field. He previously co-founded OCTIMET Oncology NV, a spin-off of Janssen Pharmaceuticals, where he served as Chief Scientific Officer and led development of the MET/OCT-2 inhibitor OMO-1 through phase 1/2 clinical trials and raised over 12 million euros in funding.
Where does Timothy Perera work?
Timothy Perera is Founder & CEO of Deuteroncology.
What companies did Timothy Perera found?
Timothy Perera founded Deuteroncology.
Where did Timothy Perera go to school?
Timothy Perera studied at University of London (Bachelor's Degree, Cell Biology); Johnson and Johnson University (Management Fundamentals I and II (2003-2004-2008)); Univeristy of Essex (Doctor of Philosophy (Ph.D.), Cell Biology).

Founder mafias

Harvard Business School mafia885

Also came through, then founded or led a company.

Tim DraperMBAFounded Draper AssociatesMike Maples JrMBAFounded Pattern BreakersHristo BorisovOPM Class 64Founded PayhawkNoubar AfeyanVisiting LecturerFounded ProFound Therapeutics +13Wade MyersMBAFounded RealManage +6Nick PerrettPLDFounded Prosper list view +4

+ 878 more

Johnson & Johnson mafia70

Also came through, then founded or led a company.

Francisco LeonVice President & Head, Immunology Translational MedicineFounded Avalor Therapeutics +2Serge MesserlianSr. Director, US Portfolio Head, ImmunologyFounded Creyon +1Jacopo LeonardiDirector of MarketingFounded 4D Path +1Kim RodriguezDirector of SalesFounded BrainCheck +1Sid ViswanathanGlobal Operations Leadership DevelopmentFounded Alchemy Health +1Siyu HuangMarketing Leadership Development Program (MLDP)Founded Lionano +1

+ 63 more

University of London mafia35

Also came through, then founded or led a company.

Wim Van CriekingeMasterFounded Lizard +1Anand KrishnaBSc FinanceFounded Inkle +1Upeka BeeBsc. (Hons)Founded DianaHR +1Abasi Ene-ObongPhD- Barts and the London School of Medicine and DentistryFounded Syndicate Bio +1Paul CastellaBScFounded Hera BiotechSiddharth NayyarB.Sc. Economics (H)Founded Afkgaming

+ 28 more

HU University of Applied Sciences Utrecht (Hogeschool Utrecht) mafia11

Also came through, then founded or led a company.

Laurens GroenendijkYesFounded Hiber +1Alef ArendsenDNFFounded SpringSource +1Marc WesselinkBachelorFounded Just EatMicha Hernandez van LeuffenBICTFounded WerckerGiulio CantoroSummer schoolFounded Blink Last MileWouter DraijerIngenieur (Ir.)Founded SolarMente

+ 4 more

CELforPharma mafia3

Also came through, then founded or led a company.

Akeem GardnerPharma-Biotech Product & Company ValuationFounded Canurta Therapeutics WebsitePeter SchiemannPharma-Biotech Product & Company ValuationFounded iQure Pharma

Same school

Also attended University of London146

Sandra SchwarzerInvestor at Index VenturesAnneleen PeetersNon-executive Director at Capricorn Venture PartnersKarim GillaniGeneral Partner at Luge CapitalRoxanneCompliance Officer at Hummingbird VenturesRakesh MurriaCOO at Nauta CapitalJos WhiteGeneral Partner at Notion Capital

+ 140 more

Also attended CELforPharma3

Steven BiesmansPrincipal at UCB VenturesAkeem GardnerFounder at Canurta Therapeutics WebsitePeter SchiemannFounder at iQure Pharma

Also attended Harvard Business School2,000

Brad GerstnerFounder & CEO of Altimeter CapitalVictoria TreygerGeneral Partner at Felicis VenturesDeep NisharInvestment Team at General CatalystJohn KimInvestor Relations at General CatalystAdrianna MaInvestor at Index VenturesNeil RimerInvestor at Index Ventures

+ 1,994 more

Also attended HU University of Applied Sciences Utrecht (Hogeschool Utrecht)22

Marc WesselinkVenture Partner at Contrarian VenturesLaurens GroenendijkFounding Partner at DFF VenturesPatrick KerssemakersFounding Partner at DFF VenturesJob van SchelvenPartner at PureTerra VenturesJacco RolvinkCo-Head of Origination at Colesco Capital CollectiveJonė VaitulevičiūtėGeneral Partner at Firstpick

+ 16 more

Shared employers

Also worked at OCTIMET Oncology NV3

Christina TakkeManaging Partner at V-Bio VenturesShelley MargetsonManaging Partner at V-Bio VenturesJan Van den BosschePartner at Andera Partners

Also worked at Janssen, Pharmaceutical Companies of Johnson and Johnson56

Patrick LoerchBio Advisor at Amplify PartnersUmut EserVenture Partner at Magnetic VenturesLance BermanVenture Partner at Ysios CapitalJuan CuevaDirector, Early Innovation Partnering at Johnson & Johnson at Joyance PartnersPatrick ForsterInvestment Analyst at The Spartan GroupMichael KalosInvestor at 82VS

+ 50 more

Also worked at Johnson & Johnson225

Teresa ChanChief Financial Officer at Felicis VenturesKarthik ArdhanareeswaranInvestor at GV (Google Ventures)KobeFinance Director at Hummingbird VenturesMickelFinance & Risk Management at Hummingbird VenturesHal PazInvestor at Khosla VenturesNiall O'DonnellManaging Director at RiverVest Venture Partners

+ 219 more